ECSP13012716A - Compuestos y sus usos - Google Patents

Compuestos y sus usos

Info

Publication number
ECSP13012716A
ECSP13012716A ECSP13012716A ECSP13012716A EC SP13012716 A ECSP13012716 A EC SP13012716A EC SP13012716 A ECSP13012716 A EC SP13012716A EC SP13012716 A ECSP13012716 A EC SP13012716A
Authority
EC
Ecuador
Prior art keywords
compounds
formula
lactamases
restore
inhibitors
Prior art date
Application number
Other languages
English (en)
Inventor
Palanisamy Senthilkumar Udayampalayam
Maneesh Paul-Satyaseela
Shridhar Narayanan
Gopalan Balasubramanian
Aravind Appu
Senthilnathan Manickam
Hariharan Periasamy
Original Assignee
Orchid Chemicals & Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45757037&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012716(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orchid Chemicals & Pharm Ltd filed Critical Orchid Chemicals & Pharm Ltd
Publication of ECSP13012716A publication Critical patent/ECSP13012716A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/87—Compounds being unsubstituted in position 3 or with substituents other than only two methyl radicals attached in position 3, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/21—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/88—Compounds with a double bond between positions 2 and 3 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D499/883—Compounds with a double bond between positions 2 and 3 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with a substituted hydrocarbon radical attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En la presente invención se describen compuestos y su uso en el tratamiento de infecciones. El compuesto de la fórmula (I), sus derivados, análogos, formas tautoméricas, estereoisómeros, polimorfos, solvatos, sales farmacéuticamente aceptables y composiciones farmacéuticas aquí descritas, también son útiles como inhibidores de ?-lactamasa, que restauran o incrementan el espectro antibiótico de un agente antibiótico adecuado. Los compuestos de la fórmula (I) actúan como inhibidores de ?-lactamasas. Estos compuestos restauran/potencían las actividades de los antibióticos de ?-lactam contra carbapenemasas. Estos compuestos encuentran uso en el método de diagnóstico para detectar ?-lactamasas. Fórmula (I)
ECSP13012716 2010-11-25 2013-06-24 Compuestos y sus usos ECSP13012716A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3555CH2010 2010-11-25
IN3096CH2011 2011-09-09

Publications (1)

Publication Number Publication Date
ECSP13012716A true ECSP13012716A (es) 2013-08-30

Family

ID=45757037

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012716 ECSP13012716A (es) 2010-11-25 2013-06-24 Compuestos y sus usos

Country Status (30)

Country Link
US (1) US10201532B2 (es)
EP (1) EP2642992B1 (es)
JP (1) JP5961177B2 (es)
KR (1) KR101933084B1 (es)
CN (2) CN103347515B (es)
AP (1) AP2013006947A0 (es)
AU (1) AU2011333305B2 (es)
BR (1) BR112013012735B1 (es)
CA (1) CA2818100C (es)
CL (1) CL2013001482A1 (es)
CO (1) CO6781486A2 (es)
CR (1) CR20130306A (es)
DK (1) DK2642992T3 (es)
EA (1) EA030662B1 (es)
EC (1) ECSP13012716A (es)
ES (1) ES2859639T3 (es)
FR (1) FR24C1035I2 (es)
HU (1) HUE053623T2 (es)
IL (1) IL226538A (es)
MA (1) MA34760B1 (es)
MX (2) MX375266B (es)
MY (1) MY170435A (es)
NZ (1) NZ610247A (es)
PE (1) PE20140716A1 (es)
PH (1) PH12013501042A1 (es)
SG (1) SG190877A1 (es)
SV (1) SV2013004451A (es)
UA (1) UA115966C2 (es)
WO (1) WO2012070071A1 (es)
ZA (1) ZA201303773B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2993900B1 (fr) * 2012-07-27 2016-03-25 Biomerieux Sa Procede de detection de bacteries productrices de carbapenemases de type oxa-48
TWI595007B (zh) * 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
US20140128364A1 (en) * 2012-11-05 2014-05-08 Rempex Pharmaceuticals Therapeutic uses of tigemonam and carumonam
GB201319776D0 (en) 2013-11-08 2013-12-25 Allecra Therapeutics Sas Compound
GB201408649D0 (en) * 2014-05-15 2014-07-02 Allecra Therapeutics Sas Method
JP2016010399A (ja) * 2014-06-03 2016-01-21 日水製薬株式会社 カルバペネマーゼ産生耐性菌検出用組成物
FR3024465B1 (fr) * 2014-07-30 2018-03-23 Biomerieux Caracterisation de micro-organismes par maldi-tof
EP3372587A1 (en) * 2017-03-09 2018-09-12 Centre National de la Recherche Scientifique (CNRS) 3-imidazolines as carbapenemases inhibitors
SI25892A (sl) * 2019-09-05 2021-03-31 Gorenje Gospodinjski Aparati, D.O.O. Pralni stroj, ki se polni s sprednje strani, z električnim svetlobnim telesom
JP7630179B2 (ja) * 2019-09-11 2025-02-17 テンノア・セラピューティクス・（スージョウ）・リミテッド 細菌感染症を治療するためのペナム誘導体
CN110840897B (zh) * 2019-11-28 2023-08-08 河北旺发生物科技有限公司 金属β-内酰胺酶抑制剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59118790A (ja) * 1982-12-24 1984-07-09 Taiho Yakuhin Kogyo Kk ペニシリン誘導体
US4562073A (en) 1982-12-24 1985-12-31 Taiho Pharmaceutical Company Limited Penicillin derivatives
JPS60215688A (ja) * 1984-04-09 1985-10-29 Taiho Yakuhin Kogyo Kk ペニシリン誘導体
JP2599595B2 (ja) * 1987-06-26 1997-04-09 大鵬薬品工業株式会社 ２β−置換メチルペニシラン酸誘導体、その塩及びエステル
US4891369A (en) 1986-12-03 1990-01-02 Taiho Pharmaceutical Company, Limited 2β-Substituted-methylpenicillanic acid derivatives, and salts and esters thereof
JP2648750B2 (ja) * 1988-03-02 1997-09-03 大塚化学株式会社 β−ラクタム誘導体の製造方法
PL1468697T3 (pl) 2003-04-14 2008-05-30 Wyeth Corp Kompozycje zawierające piperacyklinę i tazobaktam przydatne do wstrzykiwań
JP2008516967A (ja) 2004-10-14 2008-05-22 ワイス 乳酸ナトリウム希釈液中にピペラシリン、タゾバクタムおよびアミノカルボン酸を含む組成物
WO2008010048A2 (en) * 2006-07-12 2008-01-24 Orchid Chemicals & Pharmaceuticals Limited Novel 2-substituted methyl penam derivatives
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments

Also Published As

Publication number Publication date
CA2818100A1 (en) 2012-05-31
CL2013001482A1 (es) 2014-04-04
UA115966C2 (uk) 2018-01-25
KR101933084B1 (ko) 2018-12-28
US20140057888A1 (en) 2014-02-27
WO2012070071A1 (en) 2012-05-31
BR112013012735A2 (pt) 2017-11-07
SG190877A1 (en) 2013-07-31
CN103347515B (zh) 2017-06-06
ZA201303773B (en) 2014-11-26
MA34760B1 (fr) 2013-12-03
US10201532B2 (en) 2019-02-12
SV2013004451A (es) 2017-12-01
CN103347515A (zh) 2013-10-09
EA201300617A1 (ru) 2014-03-31
WO2012070071A9 (en) 2012-08-16
AU2011333305A1 (en) 2013-07-11
JP5961177B2 (ja) 2016-08-02
MX353447B (es) 2018-01-11
HUE053623T2 (hu) 2021-07-28
ES2859639T3 (es) 2021-10-04
KR20140052927A (ko) 2014-05-07
FR24C1035I1 (fr) 2024-12-06
BR112013012735B1 (pt) 2021-11-23
EA030662B1 (ru) 2018-09-28
MX375266B (es) 2025-03-06
MY170435A (en) 2019-07-31
NZ610247A (en) 2014-09-26
BR112013012735A8 (pt) 2021-10-26
IL226538A (en) 2017-07-31
MX2013005907A (es) 2013-12-06
EP2642992B1 (en) 2020-11-25
PH12013501042A1 (en) 2021-06-02
AP2013006947A0 (en) 2013-06-30
CN107260729B (zh) 2020-03-31
AU2011333305B2 (en) 2017-06-22
EP2642992A1 (en) 2013-10-02
JP2014504279A (ja) 2014-02-20
CA2818100C (en) 2019-07-09
FR24C1035I2 (fr) 2025-05-30
CN107260729A (zh) 2017-10-20
CO6781486A2 (es) 2013-10-31
DK2642992T3 (da) 2021-03-01
PE20140716A1 (es) 2014-07-12
CR20130306A (es) 2013-09-18

Similar Documents

Publication Publication Date Title
SV2013004451A (es) Compuestos y su uso
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
DOP2010000259A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
DOP2011000260A (es) Pirimidinas fusionadas
UY31860A (es) Piridinas de tiazolo como inhibidoras de la adn girasa
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
ECSP099722A (es) Compuestos de pirido [2, 3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cáncer
ECSP20023626A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
CO6382176A2 (es) Derivados de urea heterociclicos y metodos de uso de los mismos-332
DOP2010000374A (es) Derivados heterociclicos de la urea y sus metodos de empleo
CR20220299A (es) Derivados de becimidazol
UY32694A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
UY32316A (es) Derivados de piperidina utiles en el tratamiento de infecciones bacterianas
ECSP13012988A (es) Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia
CU20100237A7 (es) Derivados heterocíclicos de la urea y sus métodos de empleo
CU20100239A7 (es) Derivados de urea heterocíclicos para el tratamiento de las infecciones bacterianas
CU20100172A7 (es) Derivados heterocíclicos de urea y métodos de uso de los mismos-211
CU20100005A7 (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas